In addition, the involvement of certain interleukins including IL-6, IL-4, IL-17A and IL-32β in some EMT pathways signifies their specific contribution in metastastic processes, thereby warranting further work into the development of diagnostic and immunotherapeutic tools in cancer. This evidence concerns the gene IL17A and cancer.